Standout Papers

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatmen... 2018 2026 2020 2023 359
  1. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 (2018)
    Yu Jeong Bang, Eduardo Yañez Ruiz et al. Annals of Oncology

Immediate Impact

4 from Science/Nature 62 standout
Sub-graph 1 of 19

Citing Papers

Neuronal substance P drives metastasis through an extracellular RNA–TLR7 axis
2024 StandoutNature
Cancer therapy with antibodies
2024 Standout
1 intermediate paper

Works of M. Lichinitser being referenced

Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
2018 Standout
Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869
2002

Author Peers

Author Last Decade Papers Cites
M. Lichinitser 659 389 34 607 24 1.3k
Simon P. Bach 954 235 79 824 53 1.6k
J Barbier 197 142 13 458 46 1.0k
Francis Laberge 542 660 42 319 34 1.2k
Nora Sartori 1130 346 29 1048 36 1.4k
Drew K. Seisler 943 206 85 220 43 1.3k
Chi‐Young Jeong 379 402 29 431 58 1.0k
Mary K. DeBenedetti 406 92 37 863 25 1.7k
Céline Lepère 1252 470 12 250 42 1.5k
Masahiro Ohgami 177 627 17 977 35 1.4k
Joanna M. Brell 1175 495 89 211 40 1.7k

All Works

Loading papers...

Rankless by CCL
2026